Gastric mucosa during treatment with lansoprazole

Helicobacter pylori is a risk factor for argyrophil cell hyperplasia

R. Eissele, G. Brunner, B. Simon, E. Solcia, R. Arnold

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Background and Aims: The mechanisms causing progression of fundic gastritis and changes in argyrophil cell morphology in patients undergoing long-term treatment with proton pump inhibitors are unknown. The hypothesis of this study was that Helicobacter pylori is a risk factor for both gastritis and argyrophil cell hyperplasia. Methods: Forty-two patients with peptic disorders resistant to H 2-blockers were treated with 30-90 mg lansoprazole daily for up to 5 years. Serum gastrin levels, antral gastrin cells, fundic argyrophil cells, parameters of gastritis, and H. pylori infection were evaluated regularly. Results: In nonantrectomized patients, serum gastrin levels increased from a median of 76 pg/mL to 163 pg/mL within 3 months. Antral gastrin cell density increased from 175 to 267 cells/mm 2 (P <0.001), and fundic argyrophil cell density increased from 83 to 149 cells/mm 2 (P <0.001). Chronic inflammation, activity, and atrophy of the oxyntic mucosa worsened exclusively in patients with H. pylori infection. Linear and/or micronodular argyrophil cell hyperplasia was diagnosed in 2.6% of patients before iansoprazole and in 29.2% after 5 years treatment. These changes were significantly related to serum gastrin levels, H. pylori infection, chronic inflammation, and atrephy of the oxyntic mucosa. Conclusions: H. pylori represents an important factor for the progression of gastritis and the development of argyrophil cell hyperplasia during long- term treatment with lansoprazole.

Original languageEnglish
Pages (from-to)707-717
Number of pages11
JournalGastroenterology
Volume112
Issue number3
DOIs
Publication statusPublished - 1997

Fingerprint

Lansoprazole
Gastric Mucosa
Helicobacter pylori
Hyperplasia
Gastritis
Gastrins
Helicobacter Infections
Gastrin-Secreting Cells
Therapeutics
Mucous Membrane
Cell Count
Serum
Inflammation
Proton Pump Inhibitors
Atrophy
Digestion

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gastric mucosa during treatment with lansoprazole : Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. / Eissele, R.; Brunner, G.; Simon, B.; Solcia, E.; Arnold, R.

In: Gastroenterology, Vol. 112, No. 3, 1997, p. 707-717.

Research output: Contribution to journalArticle

@article{a55b71d1661d4e9cb280f2d01bc2886a,
title = "Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia",
abstract = "Background and Aims: The mechanisms causing progression of fundic gastritis and changes in argyrophil cell morphology in patients undergoing long-term treatment with proton pump inhibitors are unknown. The hypothesis of this study was that Helicobacter pylori is a risk factor for both gastritis and argyrophil cell hyperplasia. Methods: Forty-two patients with peptic disorders resistant to H 2-blockers were treated with 30-90 mg lansoprazole daily for up to 5 years. Serum gastrin levels, antral gastrin cells, fundic argyrophil cells, parameters of gastritis, and H. pylori infection were evaluated regularly. Results: In nonantrectomized patients, serum gastrin levels increased from a median of 76 pg/mL to 163 pg/mL within 3 months. Antral gastrin cell density increased from 175 to 267 cells/mm 2 (P <0.001), and fundic argyrophil cell density increased from 83 to 149 cells/mm 2 (P <0.001). Chronic inflammation, activity, and atrophy of the oxyntic mucosa worsened exclusively in patients with H. pylori infection. Linear and/or micronodular argyrophil cell hyperplasia was diagnosed in 2.6{\%} of patients before iansoprazole and in 29.2{\%} after 5 years treatment. These changes were significantly related to serum gastrin levels, H. pylori infection, chronic inflammation, and atrephy of the oxyntic mucosa. Conclusions: H. pylori represents an important factor for the progression of gastritis and the development of argyrophil cell hyperplasia during long- term treatment with lansoprazole.",
author = "R. Eissele and G. Brunner and B. Simon and E. Solcia and R. Arnold",
year = "1997",
doi = "10.1053/gast.1997.v112.pm9041231",
language = "English",
volume = "112",
pages = "707--717",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Gastric mucosa during treatment with lansoprazole

T2 - Helicobacter pylori is a risk factor for argyrophil cell hyperplasia

AU - Eissele, R.

AU - Brunner, G.

AU - Simon, B.

AU - Solcia, E.

AU - Arnold, R.

PY - 1997

Y1 - 1997

N2 - Background and Aims: The mechanisms causing progression of fundic gastritis and changes in argyrophil cell morphology in patients undergoing long-term treatment with proton pump inhibitors are unknown. The hypothesis of this study was that Helicobacter pylori is a risk factor for both gastritis and argyrophil cell hyperplasia. Methods: Forty-two patients with peptic disorders resistant to H 2-blockers were treated with 30-90 mg lansoprazole daily for up to 5 years. Serum gastrin levels, antral gastrin cells, fundic argyrophil cells, parameters of gastritis, and H. pylori infection were evaluated regularly. Results: In nonantrectomized patients, serum gastrin levels increased from a median of 76 pg/mL to 163 pg/mL within 3 months. Antral gastrin cell density increased from 175 to 267 cells/mm 2 (P <0.001), and fundic argyrophil cell density increased from 83 to 149 cells/mm 2 (P <0.001). Chronic inflammation, activity, and atrophy of the oxyntic mucosa worsened exclusively in patients with H. pylori infection. Linear and/or micronodular argyrophil cell hyperplasia was diagnosed in 2.6% of patients before iansoprazole and in 29.2% after 5 years treatment. These changes were significantly related to serum gastrin levels, H. pylori infection, chronic inflammation, and atrephy of the oxyntic mucosa. Conclusions: H. pylori represents an important factor for the progression of gastritis and the development of argyrophil cell hyperplasia during long- term treatment with lansoprazole.

AB - Background and Aims: The mechanisms causing progression of fundic gastritis and changes in argyrophil cell morphology in patients undergoing long-term treatment with proton pump inhibitors are unknown. The hypothesis of this study was that Helicobacter pylori is a risk factor for both gastritis and argyrophil cell hyperplasia. Methods: Forty-two patients with peptic disorders resistant to H 2-blockers were treated with 30-90 mg lansoprazole daily for up to 5 years. Serum gastrin levels, antral gastrin cells, fundic argyrophil cells, parameters of gastritis, and H. pylori infection were evaluated regularly. Results: In nonantrectomized patients, serum gastrin levels increased from a median of 76 pg/mL to 163 pg/mL within 3 months. Antral gastrin cell density increased from 175 to 267 cells/mm 2 (P <0.001), and fundic argyrophil cell density increased from 83 to 149 cells/mm 2 (P <0.001). Chronic inflammation, activity, and atrophy of the oxyntic mucosa worsened exclusively in patients with H. pylori infection. Linear and/or micronodular argyrophil cell hyperplasia was diagnosed in 2.6% of patients before iansoprazole and in 29.2% after 5 years treatment. These changes were significantly related to serum gastrin levels, H. pylori infection, chronic inflammation, and atrephy of the oxyntic mucosa. Conclusions: H. pylori represents an important factor for the progression of gastritis and the development of argyrophil cell hyperplasia during long- term treatment with lansoprazole.

UR - http://www.scopus.com/inward/record.url?scp=0031056626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031056626&partnerID=8YFLogxK

U2 - 10.1053/gast.1997.v112.pm9041231

DO - 10.1053/gast.1997.v112.pm9041231

M3 - Article

VL - 112

SP - 707

EP - 717

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -